semaglutide and iih Idiopathic Intracranial Hypertension the Challenge of Weight Loss Treatment and Monitoring of Idiopathic

Body weight control emerged as one of the most important outcomes of GLP-1 RAs therapy in SID, a benefit that is rarely achieved with other antihyperglycaemic treatments

Who should not take semaglutide

There is, however, a real penalty for escalating too quickly

About fifteen percent of patients are clinical non-responders to semaglutide, defined as patients who have lost less than five percent of body weight by week twelve at the therapeutic dose

Single-patient-use Pen (WEGOVY FlexTouch) Storage Prior to first use, store WEGOVY FlexTouch single-patient-use penin a refrigerator between 2C to 8C (36F to 46F)

Keep me in the loop Be the first to know about new offerings and program updates, no commitment required